Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients

Oncotarget

Volumn 8, Issue 16, 2017, Pages 27007-27021

  Mao, Yu ^a   Hao, Jian ^a   Jin, Zi Qi ^a   Niu, Yang Yang ^b   Yang, Xue ^a   Liu, Dan ^a   Cao, Rui ^a   Wu, Xiong Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN CHILDREN S HOSPITAL   (China)

Author keywords

Chinese herbal medicine; Estrogen receptor; HSP90; Metastatic breast cancer; Network pharmacology

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 90; HERBACEOUS AGENT; TUMOR MARKER;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHINESE HERB; CHINESE MEDICINE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; AGED; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; DRUG FORMULATION; FEMALE; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG COMPOUNDING; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SIGNAL TRANSDUCTION;

EID: 85017508244     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15351     Document Type: Article

References (66)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7-30
3. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiology Biomarkers & Prevention. 2016; 25: 16-27
4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-132
5. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014; 64:52-62
6. Raphael J, Verma S. Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome. Breast cancer research and treatment. 2015; 150: 473-478
7. Gennari A, Conte PF, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period. Cancer. 2005; 104: 1742-1750
8. Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast cancer research and treatment. 2016; 1-10
9. Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, Han J. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Bioscience trends.2015; 9: 16-34
10. Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, Sun X, Zhou X, Guo Y, Xu Y, Liu J, Bensoussan A. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PloS one. 2013; 8: e60338
11. Yang X, Hao J, Zhu CH, Niu YY, Ding XL, Liu C, Wu XZ. Survival benefits of Western and traditional Chinese medicine treatment for patients with pancreatic cancer. Medicine. 2015; 94
12. Hsu RJ, Hsu YC, Chen SP, Fu CL, Yu JC, Chang FW, Chen YH, Liu JM, Ho JY, Yu CP. The triterpenoids of Hibiscus syriacus induce apoptosis and inhibit cell migration in breast cancer cells. BMC complementary and alternative medicine. 2015; 15: 1
13. Iwanowycz S, Wang J, Hodge J, Wang Y, Yu F, Fan D. Emodin inhibits breast cancer growth by blocking the tumor-promoting feedforward loop between cancer cells and macrophages. Molecular cancer therapeutics. 2016; molcanther. 0987
14. Tan XL, Guo L, Wang GH. Polyporus umbellatus inhibited tumor cell proliferation and promoted tumor cell apoptosis by down-regulating AKT in breast cancer. Biomedicine & Pharmacotherapy. 2016; 83: 526-535
15. Wu CT, Lai JN, Tsai YT. The prescription pattern of Chinese herbal products that contain dang-qui and risk of endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan: a population-based study. PloS one. 2014; 9: e113887
16. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nature chemical biology. 2008; 4: 682-690
17. Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T. Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacological Research. 2016; 111: 290-302
18. Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, Xu F, Chen Z, Zhu F, Chen YZ. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 2016; 44:1069-74
19. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triplenegative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer treatment reviews. 2010; 36: 206-215
20. Calza S, Hall P, Auer G, Bjöhle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, Bergh J, Pawitan Y. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Research. 2006; 8: 1
21. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752
22. Davis AP, Grondin CJ, Lennon-Hopkins K, Saraceni-Richards C, Sciaky D, King BL, Wiegers TC, Mattingly CJ. The Comparative Toxicogenomics Database's 10th year anniversary: update 2015. Nucleic Acids Res. 2015; 43: D914-20
23. Gao L, Wang XD, Niu YY, Duan DD, Yang X, Hao J, Zhu CH, Chen D, Wang KX, Qin XM, Wu XZ. Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology. Scientific reports.2016; 6
24. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, Xu X, Li Y, Wang Y et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of cheminformatics. 2014; 6: 1
25. Xue R, Fang Z, Zhang M, Yi Z, Wen C, Shi T. TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis. Nucleic acids research. 2012; gks1100
26. Ye H, Ye L, Kang H, Zhang D, Tao L, Tang K, Liu X, Zhu R, Liu Q, Chen YZ, Li Y, Cao Z. HIT: linking herbal active ingredients to targets. Nucleic Acids Res. 2011; 39: D1055-D1059
27. Gong J, Cai C, Liu X, Ku X, Jiang H, Gao D, Li H. ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Bioinformatics. 2013; 29:1827-1829
28. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011; 27: 431-432
29. Scardoni G, Petterlini M, Laudanna C. Analyzing biological network parameters with CentiScaPe. Bioinformatics. 2009; 25: 2857-2859
30. Li J, Lu C, Jiang M, Niu X, Guo H, Li L, Bian Z, Lin N, Lu A. Traditional chinese medicine-based network pharmacology could lead to new multicompound drug discovery. Evidence-Based Complementary and Alternative Medicine. 2012; 2012
31. Zhang B, Wang X, Li S. An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin. Evidence-Based Complementary and Alternative Medicine. 2013; 2013
32. Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Crosignani P, Danzon A, Federico M, Gafà L, Grosclaude P, et al. Breast carcinoma survival in Europe and the United States. Cancer. 2004; 100: 715-722
33. Zeichner SB, Herna S, Mani A, Ambros T, Montero AJ, Mahtani RL, Ahn ER, Vogel CL. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a universitybased cancer center and review of the literature. Breast Cancer Research and Treatment. 2015; 153: 617-624
34. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 2001; 344: 783-792
35. Kawano A, Shimizu C, Hashimoto K, Kinoshita T, Tsuda H, Fujii H, Fujiwara Y. Prognostic factors for stage IV hormone receptor-positive primary metastatic breast cancer. Breast Cancer. 2013; 20: 145-151
36. Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy. Cancer. 2013; 119: 1140-1148
37. Lee YW, Chen TL, Shih YR, Tsai CL, Chang CC, Liang HH, Tseng SH, Chien SC, Wang CC. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: A population-based study. Cancer. 2014; 120: 1338-1344
38. Li Y, Zhu X, Bensussan A, Li P, Moylan E, Delaney G, McPherson L. Herbal Medicine for Hot Flushes Induced by Endocrine Therapy in Women with Breast Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med, 2016. 2016; p. 1327251
39. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J. Nutr. Gerontol. Geriatr. 2012;31, 206-238
40. Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MT, Espín JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013; 19, 6064-6093
41. Pan H, Zhou W, He W, Liu X, Ding Q, Ling L, Zha X, Wang S. Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway. Int. J. Mol.Med. 2012; 30, 337-343
42. Park CH, Chang JY, Hahm ER, Park S, Kim HK, Yang CH. Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Bioph Res Co. 2005; 328: 227-234
43. Jeong J H, An J Y, Kwon Y T, Rhee J G, Lee Y J. Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression. J Cell Biochem. 2009; 106: 73-82
44. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer let. 2008; 269: 315-325
45. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ. PhaseI clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res. 1996; 2: 659-668
46. Yoshida M, Sakai T, Hosokawa N, Marui N, Matsumoto K, Fujioka A, et al. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS let.1990; 26:10-13
47. Chien SY, Wu YC, Chung JG, Yang JS, Lu HF, Tsou MF, Wood WG, Kuo SJ, Chen DR. Quercetin-induced apoptosis acts through mitochondrial-and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Human & experimental toxicology. 2009; 28: 493-503
48. Choi EJ, Bae SM, Ahn WS. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Archives of pharmacal research.2008; 31: 1281-1285
49. Choi EJ, Ahn W S. Kaempferol induced the apoptosis via cell cycle arrest in human breast cancer MDA-MB-453 cells. Nutrition research and practice. 2008; 2: 322-325
50. Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. Journal of agricultural and food chemistry. 2001; 49: 3106-3112
51. Wang Z Y, Nixon D W. Licorice and cancer. Nutrition and cancer. 2001; 39: 1-11
52. Tamir S, Eizenberg M, Somjen D, Stern N, Shelach R, Kaye A, Vaya J. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer research. 2000; 60: 5704-5709
53. Xiao HH, Fung CY, Mok SK, Wong KC, Ho MX, Wang XL, Yao XS, Wong MS. Flavonoids from Herba epimedii selectively activate estrogen receptor alpha (ERa) and stimulate ER-dependent osteoblastic functions in UMR-106 cells[J]. The Journal of steroid biochemistry and molecular biology, 2014, 143: 141-151
54. Yap SP, Shen P, Li J, Lee LS, Yong EL. Molecular and pharmacodynamic properties of estrogenic extracts from the traditional Chinese medicinal herb, Epimedium. Journal of ethnopharmacology. 2007; 113: 218-224
55. Yong EL, Wong SP, Shen P, Gong YH, Li J, Hong Y. Standardization and evaluation of botanical mixtures: lessons from a traditional Chinese herb, Epimedium, with oestrogenic properties. Novartis Found Symp. 2007; 282: 173-188
56. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007; 109: 1721-1728
57. Miyoshi Y, Murase K, Saito M, Imamura M, Oh K. Mechanisms of estrogen receptor-a upregulation in breast cancers. Medical molecular morphology. 2010; 43: 193-196
58. Clemons M, Goss P. Estrogen and the risk of breast cancer. New England Journal of Medicine. 2001; 344: 276-285
59. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM, Castanas E. Potent inhibitory action of red wine polyphenols on humanbreast cancer cells. J. Cell. Biochem.2000; 78, 429-441
60. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D, Andò S. Estrogen receptor a mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol. Pharmacol. 2001;60, 595-602
61. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors a and β. Endocrinology. 2000; 141, 3657-3667
62. Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anti-cancer drugs. 2004; 15: 651-662
63. Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc. Soc. Exp. Biol. Med.1998; 217, 420-431
64. Pick, E., Kluger, Y., Giltnane, J. M., Moeder, C., Camp, R. L., Rimm, D. L., & Kluger, H. M. (2007). High HSP90 expression is associated with decreased survival in breast cancer. Cancer research, 67, 2932-2937
65. Järvinen, T. A., Tanner, M., Bärlund, M., Borg, A., & Isola, J. (1999). Characterization of Topoisomerase II Gene Amplification and Deletion in Breast Cancer. Genes Chromosomes and Cancer, 26, 142-150
66. Lynch BJ, Guinee DG, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Human pathology. 1997; 28: 1180-1188